Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia
T Darreh-Shori, V Jelic - Expert Opinion on Drug Safety, 2010 - Taylor & Francis
Expert Opinion on Drug Safety, 2010•Taylor & Francis
Importance of the field: Cholinesterase inhibitors are the mainstay of symptomatic therapy for
Alzheimer's disease (AD). Rivastigmine, an inhibitor of both acetylcholinesterase and
butyrylcholinesterase, is available as a transdermal patch and in oral forms. It is also
approved for the treatment of Parkinson's disease dementia (PDD) in many countries. The
objective of this article is to review the safety and tolerability profile of transdermal and oral
rivastigmine in AD and PDD patients. Areas covered in this review: Articles were identified …
Alzheimer's disease (AD). Rivastigmine, an inhibitor of both acetylcholinesterase and
butyrylcholinesterase, is available as a transdermal patch and in oral forms. It is also
approved for the treatment of Parkinson's disease dementia (PDD) in many countries. The
objective of this article is to review the safety and tolerability profile of transdermal and oral
rivastigmine in AD and PDD patients. Areas covered in this review: Articles were identified …
Importance of the field: Cholinesterase inhibitors are the mainstay of symptomatic therapy for Alzheimer's disease (AD). Rivastigmine, an inhibitor of both acetylcholinesterase and butyrylcholinesterase, is available as a transdermal patch and in oral forms. It is also approved for the treatment of Parkinson's disease dementia (PDD) in many countries. The objective of this article is to review the safety and tolerability profile of transdermal and oral rivastigmine in AD and PDD patients.
Areas covered in this review: Articles were identified by searching MEDLINE in July 2009 using the terms rivastigmine, Exelon, ENA 713 and clinical trial. All double-blind, placebo-controlled randomized trials in which rivastigmine monotherapy was administered to AD or PDD patients for longer than 2 weeks were included.
What the reader will gain: This article provides a comprehensive summary of currently available safety data on rivastigmine.
Take home message: The main adverse events reported with rivastigmine therapy are gastrointestinal in nature. However, the transdermal patch appears to reduce these side effects, allowing more patients to access higher therapeutic doses. Overall, the safety profile of rivastigmine is favorable and the improved tolerability offered by the rivastigmine patch suggests that transdermal delivery may be the best way to deliver this drug in AD and PDD patients.
Taylor & Francis Online